Jez (Andrew) Gerry

Jez (Andrew) Gerry has a strong background in preclinical research and development. Jez is currently working as the Chief Operating Officer and Head of Preclinical Development at Accession Therapeutics Limited since 2021. Prior to this, they held various positions at Adaptimmune, including VP of Preclinical Research, Director of Preclinical Research, Head of Pipeline Preclinical Cell Testing, Group Leader, and Senior Scientist. Jez began their career as a Postdoctoral Scientist at the University of Reading from 2004 to 2007.

Jez (Andrew) Gerry holds a Doctor of Philosophy (PhD) degree in Cell and Molecular Biology from the University of Reading. The duration of their education at this institution is not specified.